TScan Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

TScan Therapeutics, a biopharmaceutical company specializing in T-cell receptor engineered therapies for cancer, will participate in two upcoming investor conferences. These include the Jefferies London Healthcare Conference on November 18, 2021, and the Evercore ISI 4th Annual HealthCONx Conference on December 2, 2021. Webcasts of each fireside chat will be accessible for on-demand listening on the company’s website. TScan's lead therapies, TSC-100 and TSC-101, target hematologic malignancies and aim to prevent leukemia relapse.

WALTHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate virtually at the following upcoming investor conferences:

• Jefferies London Healthcare Conference; the fireside chat will be available for on-demand listening beginning Thursday, November 18, 2021, at 3:00 a.m. ET
  
  
• Evercore ISI 4th Annual HealthCONx Conference; the fireside chat will be held on Thursday, December 2, 2021, at 11:20 a.m. ET
  

Webcasts of each fireside chat will be available and will remain archived on the “Events and Presentations” section of the Company’s website at ir.tscan.com.

About TScan Therapeutics, Inc.

TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Contacts

TScan Therapeutics, Inc.
Heather Savelle
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

Media Contact:
David Rosen
Argot Partners
212-600-1902
david.rosen@argotpartners.com

Investor Contact:
Sherri Spear
Argot Partners
212-600-1902
sherri@argotpartners.com

FAQ

When will TScan Therapeutics participate in the Jefferies London Healthcare Conference?

TScan Therapeutics will participate in the Jefferies London Healthcare Conference on November 18, 2021, with a fireside chat available for on-demand listening starting at 3:00 a.m. ET.

What is the date of the Evercore ISI 4th Annual HealthCONx Conference for TScan Therapeutics?

The Evercore ISI 4th Annual HealthCONx Conference, where TScan Therapeutics will participate, is scheduled for December 2, 2021, at 11:20 a.m. ET.

Where can I access the webcasts of TScan Therapeutics' investor conferences?

The webcasts of TScan Therapeutics' investor conferences will be available in the 'Events and Presentations' section of the company's website at ir.tscan.com.

What are the main therapies in development by TScan Therapeutics?

TScan Therapeutics is developing T-cell receptor engineered therapies, specifically TSC-100 and TSC-101, for treating hematologic malignancies and preventing leukemia relapse.